# Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)

> **NCT00523666** · PHASE4 · UNKNOWN · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 20 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Galantamine (Reminyl®)
- **DRUG:** Placebo/Galantamine (Reminyl®)

## Key facts

- **NCT ID:** NCT00523666
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2008-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2007-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00523666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00523666, "Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00523666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*